Diseases /
Malignant Solid Tumor
Back to Diseases List
Associated Genetic Biomarkers
Overview
Malignant solid tumors most frequently harbor alterations in TP53, KRAS, PIK3CA, APC, and CDKN2A [2].
TP53 Mutation, TP53 Missense, TP53 c.217-c.1178 Missense, KRAS Mutation, and KRAS Exon 2 Mutation are the most common alterations in malignant solid tumor [2].
Biomarker-Directed Therapies
Of the biomarker-directed therapies for malignant solid tumor, 3 are FDA-approved in at least one setting and 0 have NCCN guidelines in at least one setting [3].
Entrectinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA) |
| Note: Approved for patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, that are metastatic or unresectable, and that have progressed following treatment or have no satisfactory alternative therapy. |
Disease is predicted to be resistant: -
Larotrectinib +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (FDA) |
| Note: Approved for patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, that are either metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or whose cancer has progressed following treatment. |
Disease is predicted to be resistant: -
Pembrolizumab +
Disease is predicted to be sensitive: -
|
Biomarker Criteria:
Sample must match all of the following:
|
Clinical Setting(s): Metastatic (FDA) |
| Note: FDA-approved for adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Clinical Setting(s): Metastatic (FDA) |
| Note: Indicated for unresectable or metastatic tumor mutational burden-high [≥10 mutations/megabase] solid tumors with progression following prior treatment and no satisfactory alternative treatment options. |
Clinical Trials
There are 1128 clinical trials for malignant solid tumor, of which 890 are open and 238 are completed or closed. Of the trials that contain malignant solid tumor as an inclusion criterion, 6 are early phase 1 (6 open), 699 are phase 1 (526 open), 261 are phase 1/phase 2 (216 open), 145 are phase 2 (126 open), 3 are phase 3 (2 open), 4 are phase 4 (4 open), and 10 are no phase specified (10 open).
ERBB2, MSH2, and MLH1 are the most frequent gene inclusion criteria for malignant solid tumor clinical trials [3].
Pembrolizumab, nivolumab, and ipilimumab are the most common interventions in malignant solid tumor clinical trials.
Significant Genes in Malignant Solid Tumor
ABL1 +
ABL1 is altered in 1.79% of malignant solid tumor patients [2].
ABL1 is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 4 are open and 0 are closed. Of the trials that contain ABL1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [3].
ABL2 +
ABL2 is altered in 0.81% of malignant solid tumor patients [2].
ABL2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains ABL2 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
ACBD5 +
ACBD5 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains ACBD5 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
ACVR1B +
ACVR1B is altered in 1.49% of malignant solid tumor patients [2].
ACVR1B is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains ACVR1B status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
AFAP1L2 +
AFAP1L2 is altered in 0.05% of malignant solid tumor patients [2].
AFAP1L2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains AFAP1L2 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
AFF1 +
AFF1 is altered in 0.3% of malignant solid tumor patients [2].
AFF1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains AFF1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
AKT1 +
AKT1 is altered in 1.89% of malignant solid tumor patients [2].
AKT1 is an inclusion eligibility criterion in 25 clinical trials for malignant solid tumor, of which 20 are open and 5 are closed. Of the trials that contain AKT1 status and malignant solid tumor as inclusion criteria, 10 are phase 1 (6 open), 3 are phase 1/phase 2 (3 open), and 12 are phase 2 (11 open) [3].
AKT2 +
AKT2 is altered in 1.73% of malignant solid tumor patients [2].
AKT2 is an inclusion eligibility criterion in 21 clinical trials for malignant solid tumor, of which 17 are open and 4 are closed. Of the trials that contain AKT2 status and malignant solid tumor as inclusion criteria, 8 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), and 10 are phase 2 (9 open) [3].
AKT3 +
AKT3 is altered in 1.34% of malignant solid tumor patients [2].
AKT3 is an inclusion eligibility criterion in 21 clinical trials for malignant solid tumor, of which 17 are open and 4 are closed. Of the trials that contain AKT3 status and malignant solid tumor as inclusion criteria, 8 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), and 10 are phase 2 (9 open) [3].
ALK +
ALK is altered in 3.57% of malignant solid tumor patients [2].
ALK is an inclusion eligibility criterion in 22 clinical trials for malignant solid tumor, of which 15 are open and 7 are closed. Of the trials that contain ALK status and malignant solid tumor as inclusion criteria, 5 are phase 1 (1 open), 6 are phase 1/phase 2 (3 open), and 11 are phase 2 (11 open) [3].
APC +
APC is altered in 11.81% of malignant solid tumor patients [2].
APC is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains APC status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
APH1A +
APH1A is altered in 0.64% of malignant solid tumor patients [2].
APH1A is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains APH1A status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
APOBEC3A +
APOBEC3A is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3A status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
APOBEC3B +
APOBEC3B is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3B status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
APOBEC3C +
APOBEC3C is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3C status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
APOBEC3D +
APOBEC3D is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3D status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
APOBEC3G +
APOBEC3G is altered in 1.11% of malignant solid tumor patients [2].
APOBEC3G is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3G status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
APOBEC3H +
APOBEC3H is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains APOBEC3H status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
ARAF +
ARAF is altered in 1.6% of malignant solid tumor patients [2].
ARAF is an inclusion eligibility criterion in 16 clinical trials for malignant solid tumor, of which 14 are open and 2 are closed. Of the trials that contain ARAF status and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), and 5 are phase 2 (4 open) [3].
ARID1A +
ARID1A is altered in 9.46% of malignant solid tumor patients [2].
ARID1A is an inclusion eligibility criterion in 18 clinical trials for malignant solid tumor, of which 16 are open and 2 are closed. Of the trials that contain ARID1A status and malignant solid tumor as inclusion criteria, 9 are phase 1 (9 open), 5 are phase 1/phase 2 (3 open), and 4 are phase 2 (4 open) [3].
ASXL1 +
ASXL1 is altered in 3.73% of malignant solid tumor patients [2].
ASXL1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains ASXL1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
ATM +
ATM is altered in 5.8% of malignant solid tumor patients [2].
ATM is an inclusion eligibility criterion in 43 clinical trials for malignant solid tumor, of which 38 are open and 5 are closed. Of the trials that contain ATM status and malignant solid tumor as inclusion criteria, 17 are phase 1 (14 open), 7 are phase 1/phase 2 (5 open), and 19 are phase 2 (19 open) [3].
ATR +
ATR is altered in 3.15% of malignant solid tumor patients [2].
ATR is an inclusion eligibility criterion in 29 clinical trials for malignant solid tumor, of which 24 are open and 5 are closed. Of the trials that contain ATR status and malignant solid tumor as inclusion criteria, 12 are phase 1 (9 open), 7 are phase 1/phase 2 (5 open), and 10 are phase 2 (10 open) [3].
ATRX +
ATRX is altered in 5.72% of malignant solid tumor patients [2].
ATRX is an inclusion eligibility criterion in 17 clinical trials for malignant solid tumor, of which 15 are open and 2 are closed. Of the trials that contain ATRX status and malignant solid tumor as inclusion criteria, 8 are phase 1 (8 open), 4 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [3].
AXL +
AXL is altered in 2.2% of malignant solid tumor patients [2].
AXL is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain AXL status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [3].
BAP1 +
BAP1 is altered in 2.57% of malignant solid tumor patients [2].
BAP1 is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 4 are open and 0 are closed. Of the trials that contain BAP1 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
BARD1 +
BARD1 is altered in 1.56% of malignant solid tumor patients [2].
BARD1 is an inclusion eligibility criterion in 32 clinical trials for malignant solid tumor, of which 28 are open and 4 are closed. Of the trials that contain BARD1 status and malignant solid tumor as inclusion criteria, 14 are phase 1 (12 open), 6 are phase 1/phase 2 (4 open), and 12 are phase 2 (12 open) [3].
BCL2 +
BCL2 is altered in 0.61% of malignant solid tumor patients [2].
BCL2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains BCL2 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
BCR +
BCR is altered in 1.41% of malignant solid tumor patients [2].
BCR is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 3 are open and 0 are closed. Of the trials that contain BCR status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [3].
BLM +
BLM is altered in 2.22% of malignant solid tumor patients [2].
BLM is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 2 are open and 1 is closed. Of the trials that contain BLM status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [3].
BRAF +
BRAF is altered in 6.59% of malignant solid tumor patients [2].
BRAF is an inclusion eligibility criterion in 63 clinical trials for malignant solid tumor, of which 46 are open and 17 are closed. Of the trials that contain BRAF status and malignant solid tumor as inclusion criteria, 34 are phase 1 (20 open), 9 are phase 1/phase 2 (9 open), and 20 are phase 2 (17 open) [3].
BRCA1 +
BRCA1 is altered in 3.21% of malignant solid tumor patients [2].
BRCA1 is an inclusion eligibility criterion in 53 clinical trials for malignant solid tumor, of which 44 are open and 9 are closed. Of the trials that contain BRCA1 status and malignant solid tumor as inclusion criteria, 24 are phase 1 (19 open), 11 are phase 1/phase 2 (7 open), and 18 are phase 2 (18 open) [3].
BRCA2 +
BRCA2 is altered in 5.45% of malignant solid tumor patients [2].
BRCA2 is an inclusion eligibility criterion in 53 clinical trials for malignant solid tumor, of which 44 are open and 9 are closed. Of the trials that contain BRCA2 status and malignant solid tumor as inclusion criteria, 24 are phase 1 (19 open), 11 are phase 1/phase 2 (7 open), and 18 are phase 2 (18 open) [3].
BRD3 +
BRD3 is altered in 2.41% of malignant solid tumor patients [2].
BRD3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains BRD3 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
BRD4 +
BRD4 is altered in 2.6% of malignant solid tumor patients [2].
BRD4 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains BRD4 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
BRIP1 +
BRIP1 is altered in 2.82% of malignant solid tumor patients [2].
BRIP1 is an inclusion eligibility criterion in 33 clinical trials for malignant solid tumor, of which 29 are open and 4 are closed. Of the trials that contain BRIP1 status and malignant solid tumor as inclusion criteria, 15 are phase 1 (13 open), 6 are phase 1/phase 2 (4 open), and 12 are phase 2 (12 open) [3].
BTRC +
BTRC is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains BTRC status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
C11ORF30 +
C11orf30 is altered in 0.52% of malignant solid tumor patients [2].
C11orf30 is an inclusion eligibility criterion in 13 clinical trials for malignant solid tumor, of which 11 are open and 2 are closed. Of the trials that contain C11orf30 status and malignant solid tumor as inclusion criteria, 5 are phase 1 (5 open), 4 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [3].
CCDC6 +
CCDC6 is altered in 0.29% of malignant solid tumor patients [2].
CCDC6 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CCDC6 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CCNA1 +
CCNA1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CCNA1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CCNA2 +
CCNA2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CCNA2 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CCNB1 +
CCNB1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CCNB1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CCNB2 +
CCNB2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CCNB2 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CCNB3 +
CCNB3 is altered in 0.03% of malignant solid tumor patients [2].
CCNB3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CCNB3 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CCND1 +
CCND1 is altered in 4.48% of malignant solid tumor patients [2].
CCND1 is an inclusion eligibility criterion in 12 clinical trials for malignant solid tumor, of which 11 are open and 1 is closed. Of the trials that contain CCND1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 10 are phase 2 (9 open) [3].
CCND2 +
CCND2 is altered in 1.51% of malignant solid tumor patients [2].
CCND2 is an inclusion eligibility criterion in 8 clinical trials for malignant solid tumor, of which 7 are open and 1 is closed. Of the trials that contain CCND2 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 7 are phase 2 (6 open) [3].
CCND3 +
CCND3 is altered in 1.04% of malignant solid tumor patients [2].
CCND3 is an inclusion eligibility criterion in 8 clinical trials for malignant solid tumor, of which 7 are open and 1 is closed. Of the trials that contain CCND3 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 7 are phase 2 (6 open) [3].
CCNE1 +
CCNE1 is altered in 2.41% of malignant solid tumor patients [2].
CCNE1 is an inclusion eligibility criterion in 11 clinical trials for malignant solid tumor, of which 7 are open and 4 are closed. Of the trials that contain CCNE1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 9 are phase 2 (6 open) [3].
CCNE2 +
CCNE2 is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain CCNE2 status and malignant solid tumor as inclusion criteria, 4 are phase 2 (3 open) [3].
CD274 +
CD274 is altered in 0.98% of malignant solid tumor patients [2].
CD274 is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 3 are open and 0 are closed. Of the trials that contain CD274 status and malignant solid tumor as inclusion criteria, 3 are phase 2 (3 open) [3].
CDK1 +
CDK1 is altered in 0.81% of malignant solid tumor patients [2].
CDK1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CDK1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CDK12 +
CDK12 is altered in 3.83% of malignant solid tumor patients [2].
CDK12 is an inclusion eligibility criterion in 21 clinical trials for malignant solid tumor, of which 18 are open and 3 are closed. Of the trials that contain CDK12 status and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 4 are phase 1/phase 2 (2 open), and 8 are phase 2 (8 open) [3].
CDK2 +
CDK2 is altered in 0.17% of malignant solid tumor patients [2].
CDK2 is an inclusion eligibility criterion in 5 clinical trials for malignant solid tumor, of which 4 are open and 1 is closed. Of the trials that contain CDK2 status and malignant solid tumor as inclusion criteria, 5 are phase 2 (4 open) [3].
CDK4 +
CDK4 is altered in 2.46% of malignant solid tumor patients [2].
CDK4 is an inclusion eligibility criterion in 14 clinical trials for malignant solid tumor, of which 13 are open and 1 is closed. Of the trials that contain CDK4 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 12 are phase 2 (11 open) [3].
CDK6 +
CDK6 is altered in 1.01% of malignant solid tumor patients [2].
CDK6 is an inclusion eligibility criterion in 12 clinical trials for malignant solid tumor, of which 11 are open and 1 is closed. Of the trials that contain CDK6 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 11 are phase 2 (10 open) [3].
CDKN1A +
CDKN1A is altered in 0.96% of malignant solid tumor patients [2].
CDKN1A is an inclusion eligibility criterion in 5 clinical trials for malignant solid tumor, of which 3 are open and 2 are closed. Of the trials that contain CDKN1A status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (3 open) [3].
CDKN1B +
CDKN1B is altered in 1.96% of malignant solid tumor patients [2].
CDKN1B is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 2 are open and 2 are closed. Of the trials that contain CDKN1B status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (2 open) [3].
CDKN2A +
CDKN2A is altered in 11.23% of malignant solid tumor patients [2].
CDKN2A is an inclusion eligibility criterion in 14 clinical trials for malignant solid tumor, of which 10 are open and 4 are closed. Of the trials that contain CDKN2A status and malignant solid tumor as inclusion criteria, 4 are phase 1 (1 open) and 10 are phase 2 (9 open) [3].
CDKN2B +
CDKN2B is altered in 7.98% of malignant solid tumor patients [2].
CDKN2B is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CDKN2B status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CEP43 +
CEP43 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CEP43 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
CHD4 +
CHD4 is altered in 3.84% of malignant solid tumor patients [2].
CHD4 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains CHD4 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
CHEK1 +
CHEK1 is altered in 0.84% of malignant solid tumor patients [2].
CHEK1 is an inclusion eligibility criterion in 29 clinical trials for malignant solid tumor, of which 25 are open and 4 are closed. Of the trials that contain CHEK1 status and malignant solid tumor as inclusion criteria, 13 are phase 1 (11 open), 6 are phase 1/phase 2 (4 open), and 10 are phase 2 (10 open) [3].
CHEK2 +
CHEK2 is altered in 1.63% of malignant solid tumor patients [2].
CHEK2 is an inclusion eligibility criterion in 31 clinical trials for malignant solid tumor, of which 27 are open and 4 are closed. Of the trials that contain CHEK2 status and malignant solid tumor as inclusion criteria, 14 are phase 1 (12 open), 6 are phase 1/phase 2 (4 open), and 11 are phase 2 (11 open) [3].
CRKL +
CRKL is altered in 0.91% of malignant solid tumor patients [2].
CRKL is an inclusion eligibility criterion in 24 clinical trials for malignant solid tumor, of which 20 are open and 4 are closed. Of the trials that contain CRKL status and malignant solid tumor as inclusion criteria, 13 are phase 1 (10 open), 4 are phase 1/phase 2 (4 open), and 7 are phase 2 (6 open) [3].
CSF1R +
CSF1R is altered in 1.53% of malignant solid tumor patients [2].
CSF1R is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain CSF1R status and malignant solid tumor as inclusion criteria, 2 are phase 2 (2 open) [3].
CTNNB1 +
CTNNB1 is altered in 3.34% of malignant solid tumor patients [2].
CTNNB1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains CTNNB1 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
CYLD +
CYLD is altered in 1.74% of malignant solid tumor patients [2].
CYLD is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains CYLD status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
DAXX +
DAXX is altered in 1.57% of malignant solid tumor patients [2].
DAXX is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains DAXX status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
DDR2 +
DDR2 is altered in 2.18% of malignant solid tumor patients [2].
DDR2 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain DDR2 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) [3].
DEK +
DEK is altered in 1.13% of malignant solid tumor patients [2].
DEK is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains DEK status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
DICER1 +
DICER1 is altered in 2.55% of malignant solid tumor patients [2].
DICER1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains DICER1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
DLL4 +
DLL4 is altered in 0.0% of malignant solid tumor patients [2].
DLL4 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains DLL4 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
DNMT3A +
DNMT3A is altered in 2.49% of malignant solid tumor patients [2].
DNMT3A is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains DNMT3A status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
DVL1 +
DVL1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains DVL1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
EGFR +
EGFR is altered in 7.61% of malignant solid tumor patients [2].
EGFR is an inclusion eligibility criterion in 47 clinical trials for malignant solid tumor, of which 36 are open and 11 are closed. Of the trials that contain EGFR status and malignant solid tumor as inclusion criteria, 15 are phase 1 (9 open), 15 are phase 1/phase 2 (12 open), and 17 are phase 2 (15 open) [3].
ELL +
ELL is altered in 0.08% of malignant solid tumor patients [2].
ELL is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains ELL status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
EPCAM +
EPCAM is altered in 0.6% of malignant solid tumor patients [2].
EPCAM is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain EPCAM status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
ERBB2 +
ERBB2 is altered in 5.44% of malignant solid tumor patients [2].
ERBB2 is an inclusion eligibility criterion in 213 clinical trials for malignant solid tumor, of which 149 are open and 64 are closed. Of the trials that contain ERBB2 status and malignant solid tumor as inclusion criteria, 1 is early phase 1 (1 open), 132 are phase 1 (85 open), 55 are phase 1/phase 2 (41 open), and 25 are phase 2 (22 open) [3].
ERBB3 +
ERBB3 is altered in 3.19% of malignant solid tumor patients [2].
ERBB3 is an inclusion eligibility criterion in 6 clinical trials for malignant solid tumor, of which 5 are open and 1 is closed. Of the trials that contain ERBB3 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [3].
ERBB4 +
ERBB4 is altered in 3.41% of malignant solid tumor patients [2].
ERBB4 is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 2 are open and 1 is closed. Of the trials that contain ERBB4 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [3].
ERC1 +
ERC1 is altered in 0.08% of malignant solid tumor patients [2].
ERC1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains ERC1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
ERCC1 +
ERCC1 is altered in 0.23% of malignant solid tumor patients [2].
ERCC1 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain ERCC1 status and malignant solid tumor as inclusion criteria, 2 are phase 2 (2 open) [3].
ERCC2 +
ERCC2 is altered in 2.06% of malignant solid tumor patients [2].
ERCC2 is an inclusion eligibility criterion in 12 clinical trials for malignant solid tumor, of which 10 are open and 2 are closed. Of the trials that contain ERCC2 status and malignant solid tumor as inclusion criteria, 5 are phase 1 (5 open), 4 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
ERCC3 +
ERCC3 is altered in 1.23% of malignant solid tumor patients [2].
ERCC3 is an inclusion eligibility criterion in 12 clinical trials for malignant solid tumor, of which 10 are open and 2 are closed. Of the trials that contain ERCC3 status and malignant solid tumor as inclusion criteria, 5 are phase 1 (5 open), 4 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
ERCC4 +
ERCC4 is altered in 1.65% of malignant solid tumor patients [2].
ERCC4 is an inclusion eligibility criterion in 12 clinical trials for malignant solid tumor, of which 10 are open and 2 are closed. Of the trials that contain ERCC4 status and malignant solid tumor as inclusion criteria, 5 are phase 1 (5 open), 4 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
ERCC5 +
ERCC5 is altered in 2.18% of malignant solid tumor patients [2].
ERCC5 is an inclusion eligibility criterion in 12 clinical trials for malignant solid tumor, of which 10 are open and 2 are closed. Of the trials that contain ERCC5 status and malignant solid tumor as inclusion criteria, 5 are phase 1 (5 open), 4 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
ERCC6 +
ERCC6 is altered in 0.91% of malignant solid tumor patients [2].
ERCC6 is an inclusion eligibility criterion in 12 clinical trials for malignant solid tumor, of which 10 are open and 2 are closed. Of the trials that contain ERCC6 status and malignant solid tumor as inclusion criteria, 5 are phase 1 (5 open), 4 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
ETV6 +
ETV6 is altered in 2.2% of malignant solid tumor patients [2].
ETV6 is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 3 are open and 0 are closed. Of the trials that contain ETV6 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [3].
EXO1 +
EXO1 is altered in 2.5% of malignant solid tumor patients [2].
EXO1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains EXO1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
EZH2 +
EZH2 is altered in 1.19% of malignant solid tumor patients [2].
EZH2 is an inclusion eligibility criterion in 5 clinical trials for malignant solid tumor, of which 3 are open and 2 are closed. Of the trials that contain EZH2 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [3].
FAM175A +
FAM175A is altered in 0.54% of malignant solid tumor patients [2].
FAM175A is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FAM175A status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [3].
FANCA +
FANCA is altered in 2.82% of malignant solid tumor patients [2].
FANCA is an inclusion eligibility criterion in 32 clinical trials for malignant solid tumor, of which 28 are open and 4 are closed. Of the trials that contain FANCA status and malignant solid tumor as inclusion criteria, 14 are phase 1 (12 open), 6 are phase 1/phase 2 (4 open), and 12 are phase 2 (12 open) [3].
FANCB +
FANCB is altered in 1.71% of malignant solid tumor patients [2].
FANCB is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 23 are open and 4 are closed. Of the trials that contain FANCB status and malignant solid tumor as inclusion criteria, 11 are phase 1 (9 open), 6 are phase 1/phase 2 (4 open), and 10 are phase 2 (10 open) [3].
FANCC +
FANCC is altered in 1.04% of malignant solid tumor patients [2].
FANCC is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 23 are open and 4 are closed. Of the trials that contain FANCC status and malignant solid tumor as inclusion criteria, 11 are phase 1 (9 open), 6 are phase 1/phase 2 (4 open), and 10 are phase 2 (10 open) [3].
FANCD2 +
FANCD2 is altered in 5.03% of malignant solid tumor patients [2].
FANCD2 is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 23 are open and 4 are closed. Of the trials that contain FANCD2 status and malignant solid tumor as inclusion criteria, 11 are phase 1 (9 open), 6 are phase 1/phase 2 (4 open), and 10 are phase 2 (10 open) [3].
FANCE +
FANCE is altered in 1.49% of malignant solid tumor patients [2].
FANCE is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 23 are open and 4 are closed. Of the trials that contain FANCE status and malignant solid tumor as inclusion criteria, 11 are phase 1 (9 open), 6 are phase 1/phase 2 (4 open), and 10 are phase 2 (10 open) [3].
FANCF +
FANCF is altered in 1.03% of malignant solid tumor patients [2].
FANCF is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 23 are open and 4 are closed. Of the trials that contain FANCF status and malignant solid tumor as inclusion criteria, 11 are phase 1 (9 open), 6 are phase 1/phase 2 (4 open), and 10 are phase 2 (10 open) [3].
FANCG +
FANCG is altered in 1.45% of malignant solid tumor patients [2].
FANCG is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 23 are open and 4 are closed. Of the trials that contain FANCG status and malignant solid tumor as inclusion criteria, 11 are phase 1 (9 open), 6 are phase 1/phase 2 (4 open), and 10 are phase 2 (10 open) [3].
FANCI +
FANCI is altered in 2.88% of malignant solid tumor patients [2].
FANCI is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 23 are open and 4 are closed. Of the trials that contain FANCI status and malignant solid tumor as inclusion criteria, 11 are phase 1 (9 open), 6 are phase 1/phase 2 (4 open), and 10 are phase 2 (10 open) [3].
FANCL +
FANCL is altered in 1.25% of malignant solid tumor patients [2].
FANCL is an inclusion eligibility criterion in 29 clinical trials for malignant solid tumor, of which 25 are open and 4 are closed. Of the trials that contain FANCL status and malignant solid tumor as inclusion criteria, 13 are phase 1 (11 open), 6 are phase 1/phase 2 (4 open), and 10 are phase 2 (10 open) [3].
FANCM +
FANCM is altered in 5.24% of malignant solid tumor patients [2].
FANCM is an inclusion eligibility criterion in 27 clinical trials for malignant solid tumor, of which 23 are open and 4 are closed. Of the trials that contain FANCM status and malignant solid tumor as inclusion criteria, 11 are phase 1 (9 open), 6 are phase 1/phase 2 (4 open), and 10 are phase 2 (10 open) [3].
FBXW7 +
FBXW7 is altered in 3.82% of malignant solid tumor patients [2].
FBXW7 is an inclusion eligibility criterion in 5 clinical trials for malignant solid tumor, of which 4 are open and 1 is closed. Of the trials that contain FBXW7 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (4 open) [3].
FEN1 +
FEN1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FEN1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
FGF1 +
FGF1 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF1 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF10 +
FGF10 is altered in 1.39% of malignant solid tumor patients [2].
FGF10 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF10 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF11 +
FGF11 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF11 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF12 +
FGF12 is altered in 0.02% of malignant solid tumor patients [2].
FGF12 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF12 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF13 +
FGF13 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF13 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF14 +
FGF14 is altered in 0.41% of malignant solid tumor patients [2].
FGF14 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF14 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF16 +
FGF16 is altered in 0.0% of malignant solid tumor patients [2].
FGF16 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF16 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF17 +
FGF17 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF17 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF18 +
FGF18 is altered in 0.01% of malignant solid tumor patients [2].
FGF18 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF18 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF19 +
FGF19 is altered in 4.49% of malignant solid tumor patients [2].
FGF19 is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 2 are open and 1 is closed. Of the trials that contain FGF19 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (2 open) [3].
FGF2 +
FGF2 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF2 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF20 +
FGF20 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF20 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF21 +
FGF21 is altered in 0.0% of malignant solid tumor patients [2].
FGF21 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF21 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF22 +
FGF22 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF22 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF23 +
FGF23 is altered in 1.5% of malignant solid tumor patients [2].
FGF23 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF23 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF3 +
FGF3 is altered in 4.51% of malignant solid tumor patients [2].
FGF3 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF3 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF4 +
FGF4 is altered in 4.37% of malignant solid tumor patients [2].
FGF4 is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 2 are open and 1 is closed. Of the trials that contain FGF4 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (2 open) [3].
FGF5 +
FGF5 is altered in 0.82% of malignant solid tumor patients [2].
FGF5 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF5 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF6 +
FGF6 is altered in 1.63% of malignant solid tumor patients [2].
FGF6 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF6 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF7 +
FGF7 is altered in 0.82% of malignant solid tumor patients [2].
FGF7 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF7 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF8 +
FGF8 is altered in 0.01% of malignant solid tumor patients [2].
FGF8 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF8 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGF9 +
FGF9 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain FGF9 status and malignant solid tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [3].
FGFR1 +
FGFR1 is altered in 3.94% of malignant solid tumor patients [2].
FGFR1 is an inclusion eligibility criterion in 23 clinical trials for malignant solid tumor, of which 18 are open and 5 are closed. Of the trials that contain FGFR1 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (2 open), 5 are phase 1/phase 2 (4 open), 11 are phase 2 (11 open), and 1 is phase 4 (1 open) [3].
FGFR2 +
FGFR2 is altered in 2.22% of malignant solid tumor patients [2].
FGFR2 is an inclusion eligibility criterion in 29 clinical trials for malignant solid tumor, of which 22 are open and 7 are closed. Of the trials that contain FGFR2 status and malignant solid tumor as inclusion criteria, 9 are phase 1 (3 open), 5 are phase 1/phase 2 (4 open), 11 are phase 2 (11 open), 1 is phase 4 (1 open), and 3 are no phase specified (3 open) [3].
FGFR3 +
FGFR3 is altered in 2.65% of malignant solid tumor patients [2].
FGFR3 is an inclusion eligibility criterion in 23 clinical trials for malignant solid tumor, of which 17 are open and 6 are closed. Of the trials that contain FGFR3 status and malignant solid tumor as inclusion criteria, 7 are phase 1 (2 open), 4 are phase 1/phase 2 (3 open), 11 are phase 2 (11 open), and 1 is phase 4 (1 open) [3].
FGFR4 +
FGFR4 is altered in 1.92% of malignant solid tumor patients [2].
FGFR4 is an inclusion eligibility criterion in 12 clinical trials for malignant solid tumor, of which 10 are open and 2 are closed. Of the trials that contain FGFR4 status and malignant solid tumor as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), 5 are phase 2 (5 open), and 1 is phase 4 (1 open) [3].
FIGF +
FIGF is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FIGF status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
FLCN +
FLCN is altered in 1.61% of malignant solid tumor patients [2].
FLCN is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FLCN status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
FLT1 +
FLT1 is altered in 3.43% of malignant solid tumor patients [2].
FLT1 is an inclusion eligibility criterion in 5 clinical trials for malignant solid tumor, of which 4 are open and 1 is closed. Of the trials that contain FLT1 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 4 are phase 2 (3 open) [3].
FLT3 +
FLT3 is altered in 2.42% of malignant solid tumor patients [2].
FLT3 is an inclusion eligibility criterion in 6 clinical trials for malignant solid tumor, of which 4 are open and 2 are closed. Of the trials that contain FLT3 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) and 4 are phase 2 (3 open) [3].
FLT4 +
FLT4 is altered in 3.34% of malignant solid tumor patients [2].
FLT4 is an inclusion eligibility criterion in 4 clinical trials for malignant solid tumor, of which 3 are open and 1 is closed. Of the trials that contain FLT4 status and malignant solid tumor as inclusion criteria, 4 are phase 2 (3 open) [3].
FZD1 +
FZD1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD10 +
FZD10 is altered in 0.01% of malignant solid tumor patients [2].
FZD10 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD10 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD2 +
FZD2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD2 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD3 +
FZD3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD3 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD4 +
FZD4 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD4 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD5 +
FZD5 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD5 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD6 +
FZD6 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD6 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD7 +
FZD7 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD7 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD8 +
FZD8 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD8 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
FZD9 +
FZD9 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains FZD9 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
GATA3 +
GATA3 is altered in 4.02% of malignant solid tumor patients [2].
GATA3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains GATA3 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
GNA11 +
GNA11 is altered in 0.95% of malignant solid tumor patients [2].
GNA11 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains GNA11 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
GNAQ +
GNAQ is altered in 0.73% of malignant solid tumor patients [2].
GNAQ is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains GNAQ status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].
GOLGA5 +
GOLGA5 is altered in 0.12% of malignant solid tumor patients [2].
GOLGA5 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains GOLGA5 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
HDAC1 +
HDAC1 is altered in 0.76% of malignant solid tumor patients [2].
HDAC1 is an inclusion eligibility criterion in 13 clinical trials for malignant solid tumor, of which 11 are open and 2 are closed. Of the trials that contain HDAC1 status and malignant solid tumor as inclusion criteria, 5 are phase 1 (5 open), 4 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [3].
HDAC2 +
HDAC2 is altered in 0.01% of malignant solid tumor patients [2].
HDAC2 is an inclusion eligibility criterion in 13 clinical trials for malignant solid tumor, of which 11 are open and 2 are closed. Of the trials that contain HDAC2 status and malignant solid tumor as inclusion criteria, 5 are phase 1 (5 open), 4 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [3].
HGF +
HGF is altered in 2.43% of malignant solid tumor patients [2].
HGF is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains HGF status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
HOOK3 +
HOOK3 is altered in 0.11% of malignant solid tumor patients [2].
HOOK3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains HOOK3 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
HRAS +
HRAS is altered in 1.02% of malignant solid tumor patients [2].
HRAS is an inclusion eligibility criterion in 26 clinical trials for malignant solid tumor, of which 21 are open and 5 are closed. Of the trials that contain HRAS status and malignant solid tumor as inclusion criteria, 14 are phase 1 (10 open), 5 are phase 1/phase 2 (4 open), and 7 are phase 2 (7 open) [3].
IDH1 +
IDH1 is altered in 2.96% of malignant solid tumor patients [2].
IDH1 is an inclusion eligibility criterion in 14 clinical trials for malignant solid tumor, of which 12 are open and 2 are closed. Of the trials that contain IDH1 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (4 open), 1 is phase 1/phase 2 (1 open), and 7 are phase 2 (7 open) [3].
IDH2 +
IDH2 is altered in 1.02% of malignant solid tumor patients [2].
IDH2 is an inclusion eligibility criterion in 8 clinical trials for malignant solid tumor, of which 6 are open and 2 are closed. Of the trials that contain IDH2 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 5 are phase 2 (5 open) [3].
INPP4A +
INPP4A is altered in 1.38% of malignant solid tumor patients [2].
INPP4A is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains INPP4A status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
INPP4B +
INPP4B is altered in 1.41% of malignant solid tumor patients [2].
INPP4B is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains INPP4B status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
INPP5D +
INPP5D is altered in 0.12% of malignant solid tumor patients [2].
INPP5D is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains INPP5D status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
INPPL1 +
INPPL1 is altered in 3.47% of malignant solid tumor patients [2].
INPPL1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains INPPL1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
IRS2 +
IRS2 is altered in 3.16% of malignant solid tumor patients [2].
IRS2 is an inclusion eligibility criterion in 12 clinical trials for malignant solid tumor, of which 9 are open and 3 are closed. Of the trials that contain IRS2 status and malignant solid tumor as inclusion criteria, 4 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), and 5 are phase 2 (4 open) [3].
JAG1 +
JAG1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains JAG1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
JAK1 +
JAK1 is altered in 2.02% of malignant solid tumor patients [2].
JAK1 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain JAK1 status and malignant solid tumor as inclusion criteria, 2 are phase 2 (1 open) [3].
JAK2 +
JAK2 is altered in 2.01% of malignant solid tumor patients [2].
JAK2 is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 1 is open and 2 are closed. Of the trials that contain JAK2 status and malignant solid tumor as inclusion criteria, 3 are phase 2 (1 open) [3].
JAK3 +
JAK3 is altered in 2.04% of malignant solid tumor patients [2].
JAK3 is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain JAK3 status and malignant solid tumor as inclusion criteria, 2 are phase 2 (1 open) [3].
KDM6A +
KDM6A is altered in 3.73% of malignant solid tumor patients [2].
KDM6A is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain KDM6A status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) [3].
KDR +
KDR is altered in 3.28% of malignant solid tumor patients [2].
KDR is an inclusion eligibility criterion in 6 clinical trials for malignant solid tumor, of which 4 are open and 2 are closed. Of the trials that contain KDR status and malignant solid tumor as inclusion criteria, 2 are phase 1 (1 open) and 4 are phase 2 (3 open) [3].
KEAP1 +
KEAP1 is altered in 3.79% of malignant solid tumor patients [2].
KEAP1 is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 2 are open and 1 is closed. Of the trials that contain KEAP1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].
KIAA1217 +
KIAA1217 is altered in 0.1% of malignant solid tumor patients [2].
KIAA1217 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains KIAA1217 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
KIF5B +
KIF5B is altered in 0.28% of malignant solid tumor patients [2].
KIF5B is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains KIF5B status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
KIT +
KIT is altered in 3.15% of malignant solid tumor patients [2].
KIT is an inclusion eligibility criterion in 24 clinical trials for malignant solid tumor, of which 19 are open and 5 are closed. Of the trials that contain KIT status and malignant solid tumor as inclusion criteria, 8 are phase 1 (5 open), 4 are phase 1/phase 2 (4 open), and 12 are phase 2 (10 open) [3].
KMT2A +
KMT2A is altered in 4.65% of malignant solid tumor patients [2].
KMT2A is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains KMT2A status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
KMT2C +
KMT2C is altered in 6.2% of malignant solid tumor patients [2].
KMT2C is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains KMT2C status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
KMT2D +
KMT2D is altered in 10.18% of malignant solid tumor patients [2].
KMT2D is an inclusion eligibility criterion in 3 clinical trials for malignant solid tumor, of which 2 are open and 1 is closed. Of the trials that contain KMT2D status and malignant solid tumor as inclusion criteria, 3 are phase 1 (2 open) [3].
KRAS +
KRAS is altered in 17.89% of malignant solid tumor patients [2].
KRAS is an inclusion eligibility criterion in 65 clinical trials for malignant solid tumor, of which 47 are open and 18 are closed. Of the trials that contain KRAS status and malignant solid tumor as inclusion criteria, 36 are phase 1 (22 open), 19 are phase 1/phase 2 (16 open), and 10 are phase 2 (9 open) [3].
LRP5 +
LRP5 is altered in 0.03% of malignant solid tumor patients [2].
LRP5 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains LRP5 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
LRP6 +
LRP6 is altered in 0.01% of malignant solid tumor patients [2].
LRP6 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains LRP6 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].
MAGI2 +
MAGI2 is altered in 0.93% of malignant solid tumor patients [2].
MAGI2 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains MAGI2 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
MAML1 +
MAML1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains MAML1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
MAP2K1 +
MAP2K1 is altered in 1.05% of malignant solid tumor patients [2].
MAP2K1 is an inclusion eligibility criterion in 19 clinical trials for malignant solid tumor, of which 17 are open and 2 are closed. Of the trials that contain MAP2K1 status and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), and 8 are phase 2 (7 open) [3].
MAP2K2 +
MAP2K2 is altered in 0.92% of malignant solid tumor patients [2].
MAP2K2 is an inclusion eligibility criterion in 17 clinical trials for malignant solid tumor, of which 16 are open and 1 is closed. Of the trials that contain MAP2K2 status and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), and 6 are phase 2 (6 open) [3].
MAP2K4 +
MAP2K4 is altered in 2.18% of malignant solid tumor patients [2].
MAP2K4 is an inclusion eligibility criterion in 15 clinical trials for malignant solid tumor, of which 14 are open and 1 is closed. Of the trials that contain MAP2K4 status and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [3].
MAP3K1 +
MAP3K1 is altered in 3.56% of malignant solid tumor patients [2].
MAP3K1 is an inclusion eligibility criterion in 16 clinical trials for malignant solid tumor, of which 14 are open and 2 are closed. Of the trials that contain MAP3K1 status and malignant solid tumor as inclusion criteria, 10 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [3].
MAPK1 +
MAPK1 is altered in 0.9% of malignant solid tumor patients [2].
MAPK1 is an inclusion eligibility criterion in 17 clinical trials for malignant solid tumor, of which 15 are open and 2 are closed. Of the trials that contain MAPK1 status and malignant solid tumor as inclusion criteria, 9 are phase 1 (8 open), 2 are phase 1/phase 2 (2 open), and 6 are phase 2 (5 open) [3].
MAPK3 +
MAPK3 is altered in 0.84% of malignant solid tumor patients [2].
MAPK3 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains MAPK3 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
MCL1 +
MCL1 is altered in 1.97% of malignant solid tumor patients [2].
MCL1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains MCL1 status and malignant solid tumor as inclusion criteria, 1 is phase 2 (0 open) [3].
MCPH1 +
MCPH1 is altered in 0.04% of malignant solid tumor patients [2].
MCPH1 is an inclusion eligibility criterion in 15 clinical trials for malignant solid tumor, of which 12 are open and 3 are closed. Of the trials that contain MCPH1 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (4 open), 4 are phase 1/phase 2 (3 open), and 5 are phase 2 (5 open) [3].
MDM2 +
MDM2 is altered in 3.54% of malignant solid tumor patients [2].
MDM2 is an inclusion eligibility criterion in 17 clinical trials for malignant solid tumor, of which 14 are open and 3 are closed. Of the trials that contain MDM2 status and malignant solid tumor as inclusion criteria, 8 are phase 1 (7 open), 4 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [3].
MDM4 +
MDM4 is altered in 1.35% of malignant solid tumor patients [2].
MDM4 is an inclusion eligibility criterion in 14 clinical trials for malignant solid tumor, of which 12 are open and 2 are closed. Of the trials that contain MDM4 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [3].
MECOM +
MECOM is altered in 1.73% of malignant solid tumor patients [2].
MECOM is an inclusion eligibility criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain MECOM status and malignant solid tumor as inclusion criteria, 2 are phase 1 (2 open) [3].
MED12 +
MED12 is altered in 3.77% of malignant solid tumor patients [2].
MED12 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains MED12 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) [3].
MERTK +
MERTK is altered in 3.76% of malignant solid tumor patients [2].
MERTK is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains MERTK status and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [3].
MET +
MET is altered in 2.83% of malignant solid tumor patients [2].
MET is an inclusion eligibility criterion in 37 clinical trials for malignant solid tumor, of which 22 are open and 15 are closed. Of the trials that contain MET status and malignant solid tumor as inclusion criteria, 15 are phase 1 (5 open), 8 are phase 1/phase 2 (5 open), and 14 are phase 2 (12 open) [3].
MLF1 +
MLF1 is altered in 0.14% of malignant solid tumor patients [2].
MLF1 is an inclusion eligibility criterion in 13 clinical trials for malignant solid tumor, of which 11 are open and 2 are closed. Of the trials that contain MLF1 status and malignant solid tumor as inclusion criteria, 6 are phase 1 (6 open), 4 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [3].
MLH1 +
MLH1 is altered in 1.38% of malignant solid tumor patients [2].
MLH1 is an inclusion eligibility criterion in 75 clinical trials for malignant solid tumor, of which 67 are open and 8 are closed. Of the trials that contain MLH1 status and malignant solid tumor as inclusion criteria, 1 is early phase 1 (1 open), 38 are phase 1 (33 open), 10 are phase 1/phase 2 (8 open), and 26 are phase 2 (25 open) [3].
Pembrolizumab has evidence of efficacy in patients with MLH1 mutation in malignant solid tumor [3].
MLH3 +
MLH3 is altered in 3.07% of malignant solid tumor patients [2].
MLH3 is an inclusion eligibility criterion in 73 clinical trials for malignant solid tumor, of which 65 are open and 8 are closed. Of the trials that contain MLH3 status and malignant solid tumor as inclusion criteria, 1 is early phase 1 (1 open), 38 are phase 1 (33 open), 10 are phase 1/phase 2 (8 open), and 24 are phase 2 (23 open) [3].
Pembrolizumab has evidence of efficacy in patients with MLH3 mutation in malignant solid tumor [3].
MLLT1 +
MLLT1 is altered in 0.12% of malignant solid tumor patients [2].
MLLT1 is an inclusion eligibility criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains MLLT1 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [3].